Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

► Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1

► This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH.

Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that the Japan Patent Office (“JPO”) has approved Inventiva’s patent application
No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection.

The patent granted by the JPO expands the intellectual property protection of lanifibranor for use in patients with cirrhosis including patients with cirrhosis due to MASH/NASH, complementing the protection previously granted by the United States Patent and Trademark Office2. The approval of this patent further strengthens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate. To date, this portfolio is composed of 20 patent families directly owned by Inventiva, including 157 issued patents and more than 50 pending patent applications. The Company’s patent portfolio, with respect to lanifibranor, includes patents and patent applications directed to the product lanifibranor, the methods of treatment, the combination therapy, the processes, the formulations and diagnostic methods.

Pierre Broqua, Ph.D., Chief Scientific Officer and cofounder of Inventiva, stated: “We are delighted by the Japan Patent Office's decision to grant this patent for lanifibranor. We believe this patent not only reinforces our intellectual property position but also highlights lanifibranor’s potential in addressing significant unmet medical needs in patients with cirrhosis, in particular cirrhosis due to MASH/NASH. This new patent complements our
existing patent protection in the United States, and other regions, and strengthens lanifibranor’s position as a leading candidate for the potential treatment of MASH/NASH, cirrhosis and other fibrotic diseases.”

With up to 2.7%3 of Japan's population with MASH/NASH and no treatment approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Inventiva believes Japan could become an important market for lanifibranor, if approved. As previously disclosed, Inventiva entered into an exclusive licensing
agreement with Hepalys Pharma, Inc. in September 2023 to develop and commercialize lanifibranor for the potential treatment of MASH/NASH in Japan and South Korea.

About lanifibranor
Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce
antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three
peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor
proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR
isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial
activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation,
lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH/NASH. Inventiva
believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable
tolerability profile that has been observed in clinical trials and pre-clinical studies to date. The U.S. Food and Drug
Administration has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of
MASH/NASH.

About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva
is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.

Contacts

Inventiva

Pascaline Clerc, PhD EVP,

Strategy and Corporate Affairs

media@inventivapharma.com +1 202 499 8937

Brunswick Group

Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau

Media relations

inventiva@brunswickgroup.com +33 1 53 96 83 83

Westwicke, an ICR Company

Patricia L. Bank

Investor relations

patti.bank@westwicke.com +1 415 513-1284

Important Notice
This press release contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts,
included in this press release are forward-looking statements.
These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s intellectual property and intellectual property strategy, including potential patent terms and related adjustments or extensions, pre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, the estimated market size and patient population for lanifibranor in Japan, expectations with respect to clinical development and commercialization of lanifibranor by Hepalys Pharma, Inc., including with respect to regulatory approvals, expectations with respect to the benefits of the agreement with Hepalys Pharma, Inc., potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the expected benefit of having received Breakthrough Therapy Designation and Fast Track designation to lanifibranor for the treatment of MASH/NASH, including its impact on the development and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including Inventiva’s prospects, including Inventiva’s ability to continue as a going concern, whether Inventiva will be able to raise additional funds in connection with its review of potential financing and strategic options or otherwise, that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autorité des Marchés Financiers on April 3, 2024, and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on April 3, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption “Risk Factors”, and in our future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

1 Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

2 inventivapharma.com/wp-content/uploads/2022/11/Inventiva-PR-Lanifibranor-New-patent-US-EN-11-28-2022.pdf

3 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open. 2020 May 5;4(5):808-817.